ArticleMedicine2026
The prognostic value of hemoglobin-to-albumin ratio in critically ill patients with atrial fibrillation: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) is common in critically ill patients and contributes to poor outcomes. Existing risk scores provide limited prognostic value for overall mortality. The hemoglobin-to-albumin ratio (HAR), reflecting hematologic and nutritional-inflammatory status, may serve as a novel prognostic biomarker in this setting. We performed a retrospective cohort study using the Medical Information Mart for Intensive Care IV database (version 3.1). Adult intensive care unit patients with AF were included, excluding those with multiple admissions, hospital stay <24 hours, or missing laboratory data. The primary outcome was 28-day all-cause mortality, and the secondary outcome was 360-day mortality. Patients were stratified by HAR quartiles. Kaplan-Meier analysis, Cox proportional hazards models, and restricted cubic splines were applied. Subgroup analyses assessed consistency across clinical strata. A total of 7801 patients were included (median age 75 years; 40.9% male). The 28- and 360-day mortality rates were 20.1% and 25.9%, respectively. Higher HAR was associated with increased mortality (log-rank P < .001). In fully adjusted Cox models, HAR independently predicted 28-day mortality (hazard ratio: 1.07, 95% confidence interval: 1.03-1.11) and 360-day mortality (hazard ratio: 1.07, 95% confidence interval: 1.04-1.11). Restricted cubic splines showed an approximately linear relationship. Subgroup analyses indicated stronger associations in older patients, those not receiving beta-blockers, and in amiodarone users at 360 days. HAR is an independent predictor of short- and long-term mortality in critically ill AF patients. As a simple and routinely available biomarker, HAR may enhance risk stratification beyond conventional clinical tools. Further prospective and multicenter studies are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.